OncoNOx (Copenhagen, Denmark) grants Inflamalps SA (Monthey, Switzerland) an exclusive option to license and develop its front-runner drug candidate OX1001 for the treatment of inflammatory diseases.

OX1001 is the front-runner drug candidate of a chemical series of NO-hybridized protease inhibitors synthetized and discovered at OncoNOx. In-vitro and in-vivo data have proven that OX1001 exerts powerful pharmacological effects in models of inflammatory diseases and cancer. 

Under the terms of the agreement signed between OncoNOx and Inflamalps, Inflamalps will benefit from an exclusive license option to progress OX1001, developed by Inflamalps under the name INF101 and other NO-hybridized protease inhibitors into clinical development. The terms of the agreement have not been disclosed.

‘’We are pleased to sign this agreement with the highly qualified management team of Inflamalps’’, said Mai-Britt Zocca, Chief Executive Officer, OncoNox. ‘’We are very confident that this newly funded company with a focus on inflammatory diseases of the eye will be the best partner to drive the project to an Investigational New Drug (IND) stage and then ensure its rapid clinical development’’

 

‘’We are very excited to initiate the clinical development of INF101 (OX1001) in ophthalmology as its unique mechanism of action on a pathway deeply involved in several inflammatory diseases of the eye confers to this molecule a privileged position in term of potential superior efficacy and safety’’ said Vincent Mutel, Chief Executive Officer, Inflamalps.

About   OncoNOx:

OncoNOx is a biopharmaceutical company located in Copenhagen, Denmark, dedicated to the discovery and early development of
new drugs for the treatment of autoimmune diseases and cancer. Using a unique medicinal chemistry approach, OncoNOx has aimed at transforming already marketed compounds into powerful cytotoxic drugs, which potently inhibit cancer in validated animal models. For more information see www.onconox.com


About Inflamalps: Inflamalps is a pharmaceutical company aiming to establish itself as a key player in the treatment of chronic inflammatory diseases by discovering and developing novel molecules, with a focus on ophthalmological and dermatological diseases. In particular, Inflamalps will effectively advance INF101 through to pre-clinical development up to phase II clinical testing in dry eye and non-infectious uveitis. In addition Inflamalps will bring its newly discovered anti-TNFR1 molecule from research to clinical testing in dermatologic indications.
For more information www.inflamalps.com